1. Search Result
Search Result
Results for "

serotype

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

5

Biochemical Assay Reagents

4

Peptides

1

Inhibitory Antibodies

5

Natural
Products

9

Recombinant Proteins

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99214

    KBPA101

    Bacterial Infection
    Panobacumab (KBPA101) is a fully human IgM/κ monoclonal antibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 of P. aeruginosa .
    Panobacumab
  • HY-D1056C1

    LPS, from Salmonella enterica (serotype enteritidis)

    Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from S. enterica (Salmonella enterica) serotype enteritidis are lipopolysaccharide endotoxins and TLR-4 activators derived from the enteritidis serotype of S. enterica, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from S. enterica serotype enteritidis exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from S. enterica serotype enteritidis can induce systemic inflammatory responses, increasing levels of TNF-α, IFN-γ, IL-6, IL-10, and nitrate in plasma .
    Lipopolysaccharides, from S. enterica serotype enteritidis
  • HY-D1056C2

    LPS, from Salmonella enterica (serotype minnesota)

    Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from S. enterica (Salmonella enterica) serotype minnesota are lipopolysaccharide endotoxins and TLR-4 activators derived from the Minnesota serotype of S. enterica, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from S. enterica serotype minnesota exhibit a typical three-part structure: O-antigen (O-antigen), core oligosaccharide (core oligosaccharide), and lipid A (Lipid A) .
    Lipopolysaccharides, from S. enterica serotype minnesota
  • HY-D1056C3

    LPS, from Salmonella enterica (serotype typhimurium)

    Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from S. enterica (Salmonella enterica) serotype typhimurium are lipopolysaccharide endotoxins and TLR4 activators derived from serotype typhimurium of Salmonella enterica, and are classified as S-type LPS. Lipopolysaccharides, from S. enterica exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from S. enterica serotype typhimurium can modulate the fate of bacteria in dendritic cells (DC), determining the uptake, degradation, and activation of immune functions by DC cells against the bacteria .
    Lipopolysaccharides, from S. enterica serotype typhimurium
  • HY-P1916

    Bacterial Infection Inflammation/Immunology
    FliC, Serotype a (427-441), S.paratyphi A is amino acids 427 to 441 fragment belongs to the FliC, serotype a of the S. FliC epitope .
    FliC, Serotype a (427-441), S.paratyphi A
  • HY-D1056C4

    LPS, from Salmonella enterica (serotype abortus equi)

    Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from S. enterica (Salmonella enterica) serotype Abortusequi are lipopolysaccharide endotoxins and TLR-4 activators derived from the Abortusequi serotype of S. enterica, classified as a mutated R-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from S. enterica serotype abortus equi consist of core oligosaccharide (core oligosaccharide) and lipid A (Lipid A). S. enterica serotype Abortusequi is a major pathogen causing abortion in mares and is also associated with neonatal sepsis, multiple abscesses, orchitis, and polyarthritis in equids. It is primarily grouped based on lipopolysaccharides (O-antigen) and flagellin (H-antigen) .
    Lipopolysaccharides, from S. enterica serotype abortus equi
  • HY-126843

    Biochemical Assay Reagents Infection
    Chromozym U is a chromogenic agent that can be used for detection of urokinase in Shigella. Chromozym U is capable of differentiating serotypes of Shigella dysenteriae, Shigella flexneri, Shigella boydii .
    Chromozym U
  • HY-W596782

    Chaetochromin

    Fungal Endogenous Metabolite Neurological Disease
    Chaetochromin A (Compound 1) is a fungal metabolite. Chaetochromin A shows inhibitory effect on botulinum neurotoxin serotype A (BoNT A) (IC50= 24.6 μM) .
    Chaetochromin A
  • HY-42649

    Drug Derivative Neurological Disease
    NSC 14699 is a small molecule non-peptide inhibitor of botulinum neurotoxin serotype E. NSC 14699 is promising for research of therapeutic and cosmetic agents .
    NSC 14699
  • HY-138061

    Flavivirus Dengue Virus DNA/RNA Synthesis Infection
    DENV-IN-2 is a potent dengue viral replication inhibitor extracted from patent WO2018215315A1, compound 6AB, has an EC50 of 0.016 nM. DENV-IN-2 shows high potent activity against all four serotypes of the Dengue virus with EC50s ranging from 0.013 to 0.029 nM .
    DENV-IN-2
  • HY-106161
    Rupintrivir
    5 Publications Verification

    AG7088

    Virus Protease Enterovirus Infection Inflammation/Immunology
    Rupintrivirvr (AG7088), an antiviral agent, is a potent, selective and irreversible inhibitor of human rhinovirus (HRV) 3C protease. Rupintrivirvr inhibits replication of a panel of 48 different HRV serotypes in H1-HeLA and MRC-5 cell protection assays, with a mean EC50 of 0.023 μM. Rupintrivirvr shows immune-modulatory effect .
    Rupintrivir
  • HY-12349

    Enterovirus Infection
    H1PVAT is a potent and selective inhibitor of poliovirus serotypes (PV-1, PV-2, PV-3), and inhibits early stage of the replication. H1PVAT interacts with viral capsid directly and protects PV against heat inactivation .
    H1PVAT
  • HY-13637B

    BW-759 hydrate; 2'-Nor-2'-deoxyguanosine hydrate

    CMV HSV Antibiotic Nucleoside Antimetabolite/Analog Infection Cancer
    Ganciclovir (BW 759) hydrate, a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir hydrate also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir hydrate inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir hydrate has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1) and can diffuse into the brain .
    Ganciclovir hydrate
  • HY-13637
    Ganciclovir
    15+ Cited Publications

    BW 759; 2'-Nor-2'-deoxyguanosine

    CMV HSV Antibiotic Nucleoside Antimetabolite/Analog Infection Cancer
    Ganciclovir (BW 759), a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1) and can diffuse into the brain .
    Ganciclovir
  • HY-13637A
    Ganciclovir sodium
    15+ Cited Publications

    BW 759 sodium; 2'-Nor-2'-deoxyguanosine sodium

    CMV HSV Antibiotic Nucleoside Antimetabolite/Analog Infection Cancer
    Ganciclovir (BW 759) sodium, a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir sodium also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir sodium inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir sodium has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1) and can diffuse into the brain .
    Ganciclovir sodium
  • HY-13637R

    CMV HSV Antibiotic Nucleoside Antimetabolite/Analog Infection Cancer
    Ganciclovir (Standard) is the analytical standard of Ganciclovir. This product is intended for research and analytical applications. Ganciclovir (BW 759), a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1) and can diffuse into the brain .
    Ganciclovir (Standard)
  • HY-U00265

    3-Carbethoxypsoralen; 3-Ethoxycarbonylpsoralen

    Bacterial Infection
    3-CPs is a serotype capsular polysaccharide which can interfere with antibody-mediated bacterial killing.
    3-CPs
  • HY-113714

    Bacterial Infection
    C562-1101 is a small molecule potent botulinum neurotoxins E serotype (BoNT/E) inhibitor .
    C562-1101
  • HY-N11096

    Flavivirus Dengue Virus Infection Cancer
    Sinococuline is a potent anti-dengue agent that is effective against all four serotypes of dengue virus (DENV). Sinococuline is also an effective tumor cell growth inhibitor .
    Sinococuline
  • HY-138543

    Flavivirus Dengue Virus Virus Protease Infection
    NITD-688 is an orally active pan-serotype inhibitor of the dengue virus NS4B protein. NITD-688 can be used in the research of dengue virus (DENV) .
    NITD-688
  • HY-153810

    JNJ-1802

    Virus Protease Flavivirus Dengue Virus Infection
    Mosnodenvir (JNJ-1802) is an orally active pan serotype dengue virus (DENV) inhibitor, with EC50 values ranging from 0.057 to 11 nM for four dengue virus (DENV) serotypes. Mosnodenvir blocks viral replication by inhibiting the formation of complexes between two viral proteins, nonstructural protein 3 (NS3) and NS4B, thereby preventing the formation of new viral RNA. Mosnodenvir exhibits picomolar to nanomolar antiviral activity in vitro and has antiviral efficacy in mice and non-human primates .
    Mosnodenvir
  • HY-13784
    Pirodavir
    3 Publications Verification

    R77975

    Enterovirus Infection
    Pirodavir is a potent, broad-spectrum picornavirus inhibitor, and is highly active against both group A and group B rhinovirus serotypes.Pirodavir is very potent in a virus yield reduction assay (IC90=2.3 nM).
    Pirodavir
  • HY-149251

    Flavivirus Dengue Virus Infection
    DENV-IN-10 is a potent tetravalent dengue inhibitor, with EC50s of 1.36, 0.87, 0.94, and 0.95 μM against DENV-1-4 serotypes, respectively. DENV-IN-10 is a post-entry replication inhibitor that appears to be specific for cells of primate origin .
    DENV-IN-10
  • HY-P10836

    Dengue Virus Infection
    DN59 is a 33 amino acid peptide that mimics the dengue virus type 2 E stem region. DN59 inhibits all four serotypes of dengue virus (IC50: 2-5 μM) as well as other flaviviruses. N59 causes the release of genomic RNA by interacting directly with viral particles. DN59 has antiviral activity .
    DN59
  • HY-B1030
    Lanatoside C
    5 Publications Verification

    Flavivirus Dengue Virus Autophagy Enterovirus Cardiovascular Disease Cancer
    Lanatoside C is a cardiac glycoside, can be used in the treatment of congestive heart failure and cardiac arrhythmia.Lanatoside C has an IC50 of 0.19 μM for dengue virus infection in HuH-7 cells. Lanatoside C can effectively inhibit all four serotypes of dengue virus, flavivirus Kunjin, alphavirus Chikungunya, Sindbis virus and the human enterovirus 71 .
    Lanatoside C
  • HY-P4037

    HCV Infection
    HCV Core Protein (107-114) is a least immunogenic residue of the major linear HCV core regions. HCV Core Protein (107-114) is identified as the binding site within the region 101-118, which contains two residues differing between genotypes Ⅰ/Ⅱ and Ⅲ/Ⅵ. HCV Core Protein (107-114) might be a potential site for dissemination of HCV serotypes .
    HCV Core Protein (107-114)
  • HY-106161S1

    AG7088-d7

    Isotope-Labeled Compounds Enterovirus Virus Protease Infection
    Rupintrivir-d7 is a deuterated labeled Rupintrivir . Rupintrivirvr (AG7088), an antiviral agent, is a potent, selective and irreversible inhibitor of human rhinovirus (HRV) 3C protease. Rupintrivirvr inhibits replication of a panel of 48 different HRV serotypes in H1-HeLA and MRC-5 cell protection assays, with a mean EC50 of 0.023 μM. Rupintrivirvr shows immune-modulatory effect .
    Rupintrivir-d7
  • HY-139602
    (+)-JNJ-A07
    2 Publications Verification

    Flavivirus Dengue Virus Virus Protease Infection
    (+)-JNJ-A07 is a highly potent, orally active pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction. (+)-JNJ-A07 exerts nanomolar to picomolar activity against a panel of 21 clinical isolates. (+)-JNJ-A07 has a favourable pharmacokinetic profile that results in outstanding efficacy against dengue virus infection in mouse infection models .
    (+)-JNJ-A07
  • HY-B1030R

    Dengue Virus Flavivirus Autophagy Enterovirus Cardiovascular Disease Cancer
    Lanatoside C (Standard) is the analytical standard of Lanatoside C. This product is intended for research and analytical applications. Lanatoside C is a cardiac glycoside, can be used in the treatment of congestive heart failure and cardiac arrhythmia.Lanatoside C has an IC50 of 0.19 μM for dengue virus infection in HuH-7 cells. Lanatoside C can effectively inhibit all four serotypes of dengue virus, flavivirus Kunjin, alphavirus Chikungunya, Sindbis virus and the human enterovirus 71 .
    Lanatoside C (Standard)
  • HY-13637S

    BW 759-d5; 2'-Nor-2'-deoxyguanosine-d5

    Isotope-Labeled Compounds CMV HSV Antibiotic Nucleoside Antimetabolite/Analog Infection
    Ganciclovir-d5 is the deuterium labeled Ganciclovir. Ganciclovir (BW 759), a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1)[1][2][3].
    Ganciclovir-d5
  • HY-121663

    Dengue Virus Infection
    ST-148 is a novel small molecule compound that has potent inhibitory effects against all four dengue virus serotypes. In the nonlethal AG129 mouse dengue virus infection model, ST-148 significantly reduced viremia and viral load in vital organs and tended to reduce plasma cytokine levels. Compound resistance was associated with the dengue virus capsid (C) gene, and the direct interaction of ST-148 with the C protein was presumed to be achieved through the protein's built-in fluorescence change in the presence of the compound. Therefore, ST-148 appears to interact with the dengue virus C protein and inhibit one or more unique steps of the viral replication cycle.
    ST-148
  • HY-136797

    Dengue Virus Infection
    BP13944 is a potential small molecule inhibitor discovered by high-throughput screening. It can effectively inhibit the expression of dengue virus (DENV) replicons with an EC50 value of 1.03±0.09 μM. BP13944 can inhibit the replication or viral RNA synthesis of all four serotypes of DENV, but is ineffective against Japanese encephalitis virus. BP13944 may target the DENV NS3 protease, and the E66G amino acid substitution in the NS3 protease region will cause the virus to become resistant to BP13944. BP13944 has no obvious cytotoxicity. As there is currently no effective dengue vaccine and treatment, BP13944, as an effective small molecule inhibitor, may become a potential agent for the treatment of dengue in the future.
    BP13944
  • HY-D1056
    Lipopolysaccharides, from E. coli O55:B5
    Maximum Cited Publications
    247 Publications Verification

    LPS

    Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    Lipopolysaccharides, from E. coli O55:B5 (LPS, from Escherichia coli (O55:B5)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O55:B5) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O55:B5 possess the typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O55:B5 activate TLR-4 in immune cells, exhibit high pyrogenicity, and demonstrate dose and serotype specificity. Lipopolysaccharides, from E. coli O55:B5 can cause multiphasic and non-dose-dependent increases in body temperature in rats .
    Lipopolysaccharides, from E. coli O55:B5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: